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Abstract
Introduction:  The  treatment  of  patients  with  cystic  ﬁbrosis  involves  the  use  of  ototoxic  drugs,
mainly aminoglycoside  antibiotics.  Due  to  the  use  of  these  drugs,  ﬁbrocystic  patients  are  at  risk
of developing  hearing  loss.
Objective:  To  evaluate  the  hearing  of  patients  with  cystic  ﬁbrosis  by  High  Frequency  Audiometry
and Distortion  Product  Otoacoustic  Emissions.
Methods:  Cross-sectional  study.  The  study  group  consisted  of  39  patients  (7--20  years  of  age)
with cystic  ﬁbrosis  and  a  control  group  of  36  individuals  in  the  same  age  group  without  oto-
logic complaints,  with  normal  audiometric  thresholds  and  type  A  tympanometric  curves.  High
Frequency  Audiometry  and  Distortion  Product  Otoacoustic  Emissions  tests  were  conducted.
Results: The  study  group  had  signiﬁcantly  higher  thresholds  at  250,  1000,  8000,  9000,  10,000,
12,500, and  16,000  Hz  (p  =  0.004)  as  well  as  higher  prevalence  of  otoacoustic  emission  alter-
ations at  1000  and  6000  Hz  (p  =  0.001),  with  signiﬁcantly  lower  amplitudes  at  1000,  1400,  and
6000 Hz.  There  was  a  signiﬁcant  association  between  alterations  in  hearing  thresholds  in  High
Frequency  Audiometry  with  the  number  of  courses  of  aminoglycosides  administered  (p  =  0.005).
Eighty-three  percent  of  patients  who  completed  more  than  ten  courses  of  aminoglycosides  had
hearing loss  in  High  Frequency  Audiometry.
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Conclusion:  A  signiﬁcant  number  of  patients  with  cystic  ﬁbrosis  who  received  repeated  courses
of aminoglycosides  showed  alterations  in  High  Frequency  Audiometry  and  Distortion  Product
Otoacoustic  Emissions.  The  implementation  of  ten  or  more  aminoglycoside  cycles  was  associated
with alterations  in  High  Frequency  Audiometry.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
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Limiares  auditivos  em  altas  frequências  e emissões  otoacústicas  na  ﬁbrose  cística
Resumo
Introduc¸ão: O tratamento  dos  pacientes  com  ﬁbrose  cística  envolve  o  uso  de  medicamentos
ototóxicos,  principalmente  de  antibióticos  aminoglicosídeos.  Devido  ao  uso  destes  medicamen-
tos, os  pacientes  ﬁbrocísticos  apresentam  risco  de  desenvolver  perda  auditiva.
Objetivo:  Avaliar  a  audic¸ão  dos  pacientes  com  ﬁbrose  cística  pela  Audiometria  de  Altas  Fre-
quências (AAF)  e  Emissões  Otoacústicas  por  Produto  de  Distorc¸ão  (EOAPD).
Método:  Estudo  transversal.  O  grupo  de  estudo  foi  constituído  por  39  pacientes  com  idades
entre 7  e  20  anos  com  ﬁbrose  cística  e  o  grupo  controle  por  36  indivíduos  da  mesma  faixa
etária, sem  queixas  otológicas,  com  limiares  audiométricos  normais  e  curvas  timpanométricas
tipo A.  Foram  realizados  os  exames  de  audiometria  de  altas  frequências  e  emissões  otoacústicas
por produto  de  distorc¸ão.
Resultados:  O  grupo  de  estudo  apresentou  limiares  signiﬁcativamente  mais  elevados  em  250;
1000; 8.000;  9.000;  10.000;  12.500  e  16.000  Hz;  (p  =  0,004)  e  maior  prevalência  de  alterac¸ões
nas emissões  otoacústicas  em  1.000  e  6.000  Hz  (p  =  0,001);  com  amplitudes  signiﬁcativamente
mais baixas  em  1.000;  1.400  e  6.000  Hz.  Houve  associac¸ão  signiﬁcativa  entre  as  alterac¸ões
dos limiares  auditivos  na  AAF  com  o  número  de  ciclos  de  aminoglicosídeos  realizados  (p  =
0,005). Oitenta  e  três  por  cento  dos  pacientes  que  foram  submetidos  a  mais  de  3  ciclos  de
aminoglicosídeos  apresentaram  perda  auditiva  na  AAF.
Conclusão:  Um  número  signiﬁcativo  de  pacientes  com  ﬁbrose  cística  que  receberam  repetidos
ciclos de  aminoglicosídeos  apresentou  alterac¸ões  na  AAF  e  EOAPD.  A  realizac¸ão  de  10  ou  mais
ciclos de  aminoglicosídeos  esteve  associada  às  alterac¸ões  na  AAF.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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ystic  ﬁbrosis  (CF)  is  the  most  common  autosomal  reces-
ive  genetic  disease  among  white  patients.  It  affects  the
xocrine  glands,  which,  when  producing  abnormally  viscous
ecretions,  cause  a  series  of  manifestations,  mainly  respira-
ory  and  digestive.1,2 CF  is  caused  by  a  series  of  mutations  in
 gene  that  performs  cystic  ﬁbrosis  transmembrane  conduc-
ance  regulator  (CFTR)  encoding.3 Malfunction  or  absence  of
FTR  activity  causes  dehydration  of  the  mucous  secretions
nd  an  increase  in  its  viscosity,  favoring  the  obstruction  of
he  ducts  and  consequent  inﬂammation  and  ﬁbrosis.4--6
Among  the  main  agents  for  cochlear  alteration  through
totoxicity  are  AG  (aminoglycoside)  antibiotics,  widely  used
n  the  treatment  of  CF  to  combat  colonization  by  bacteria.
ue  to  the  frequent  use  of  this  type  of  drug,  patients  with
ystic  ﬁbrosis  are  at  high  risk  of  developing  hearing  loss.7--10
The  hearing  monitoring  of  patients  exposed  to  ototoxic
gents  aims  to  detect  hearing  loss  before  the  occurrence
f  impairment  at  the  range  of  frequencies  corresponding  to
peech,  with  consequent  damage  to  communication;  and  to
nable  an  early  audiological  intervention  through  individual
earing  aids  and  speech  therapy  in  those  cases  in  which
h
p
fearing  loss  is  already  evident.11--13 This  monitoring  is  espe-
ially  critical  for  the  pediatric  population,  for  even  hearing
oss  limited  to  high  frequencies  can  impair  the  child’s
anguage  development.14 Currently,  the  most  commonly
sed  procedures  to  monitor  hearing  function  in  cases  of
totoxicity  are:  pure  tone  audiometry  (PTA),  high  frequency
udiometry  (HFA),  and  otoacoustic  emissions  (OAE).13
HFA  evaluates  pure  tone  air  conduction  thresholds  in  the
--20  kHz  range,  depending  on  the  equipment.  This  is  an
mportant  test  for  the  early  detection  of  hearing  loss  caused
y  damage  to  the  base  of  the  cochlea,  as  occurs  in  cases
f  ototoxicity,  because  it  allows  the  detection  of  hearing
oss  before  reaching  the  conventionally  measured  frequency
ange  (250--8000  Hz).15,16
The  literature  presents  some  studies  on  CF  patients  eval-
ating  hearing  by  HFA.  Fausti  et  al.17 conducted  PTA  and
FA  in  53  patients  after  treatment  with  AG.  Hearing  loss
as  detected  in  47%  of  evaluated  ears,  and  HFA  alter-
tion  was  primarily  detected  in  71%  of  ears.  In  previous
tudies,  other  authors  found  similar  outcomes  with  high
earing  thresholds  in  HFA  following  AG  treatment  in  CF
atients.18,19 However,  Mulheran  et  al.20 found  that  the  risk
or  cochleotoxicity  in  CF  is  relatively  low,  approximately
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2%  for  an  intravenous  antibiotic  course.  The  authors  sug-
gested  that  the  disease  may  attenuate  the  progression  of
cochleotoxicity,  thanks  to  the  rapid  renal  clearance  of  these
drugs.  Mulheran  et  al.21 reinforced  this  assumption  with
HFA,  with  absence  of  cochleotoxicity  after  treatment  with
tobramycin  in  CF  patients.  The  authors  highlighted  the  fact
that  the  cumulative  effect  of  AG  was  not  assessed,  because
the  aim  of  their  study  was  to  evaluate  the  cochleotoxic-
ity  of  tobramycin  administered  one  to  three  times  per  day.
When  assessing  the  prevalence  of  hearing  loss  and  its  rela-
tion  to  the  use  of  antibiotics  in  CF,  Cheng  et  al.10 observed
hearing  loss  by  PTA  in  14%  of  50  patients  and  identiﬁed
the  administration  of  ten  or  more  courses  of  AG  as  a  risk
factor.
Examination  by  OAE  does  not  require  that  the  patient
provides  responses,  and  this  test  is  very  suitable  for  small
children  and  even  for  adults  unable  to  respond  to  tests  such
as  audiometry.22 In  addition,  changes  in  OAE  may  reﬂect
cochlear  damage  that  is  not  as  yet  detectable  by  audiom-
etry.  Decreases  in  amplitude  and  in  the  dynamic  area  of
responses  and/or  loss  of  distortion  product  OAE  (DPOAE)
response  can  result  if  there  is  a  change  in  the  function  of
outer  hair  cells.23
In  a  study  of  CF  patients  and  a  control  group,  Mulheran
et  al.24 observed  normal  hearing  thresholds  in  both  groups;
however,  these  authors  detected  a  signiﬁcant  increase  of
the  stimulus  required  to  generate  DPOAE  at  4  kHz  in  CF
group.  The  authors  suggested  that  this  rise  could  repre-
sent  one  of  the  ﬁrst  alterations  occurring  in  outer  hair  cells,
caused  by  gentamicin.  Stavroulaki  et  al.8 found  that  DPOAE
is  more  sensitive  than  PTA  in  detecting  cochlear  changes
after  the  use  of  gentamicin.  Using  DPOAE,  other  authors25,26
also  found  cochlear  alterations  occurring  prior  to  changes  in
hearing  threshold.  However,  some  authors,  in  their  studies
with  ototoxic  agents,  claim  that  HFA  is  more  effective  than
OAE  to  detect  hearing  loss.23,27--29
In  Brazil,  there  are  few  studies  on  CF  patients’  hearing
utilizing  high  frequency  audiometry.  Therefore,  this  study
aimed  to  evaluate  hearing  thresholds  testing  high  frequen-
cies  and  using  DPOAE  in  CF  patients  from  this  institution.
Methods
This  study  was  approved  under  No.  120096  by  the  Ethics
Committee  of  the  institution.
This  was  an  observational,  cross-sectional  study.  The  pop-
ulation  studied  was  composed  of  a  study  group  (SG)  with  39
children  and  adolescents  referred  from  adult  and  pediatric
cystic  ﬁbrosis  (CF)  outpatient  clinics  from  this  institution.
The  control  group  (CG)  comprised  36  children  and  adoles-
cents  from  the  institution’s  otorhinolaryngology  outpatient
clinic,  trainees,  and  children  of  employees  of  the  institution
and  students  of  a  state  elementary  school.
The  inclusion  criteria  for  the  study  group  were  as  fol-
lows:  individuals  with  a  conﬁrmed  diagnosis  of  CF,  aged  7--20
years,  treated  at  the  CF  outpatient  clinic,  with  type  A  tym-
panometric  curve30 compatible  with  a  middle  ear  without
otological  abnormalities.  For  the  control  group,  inclusion
criteria  were  individuals  aged  7--20  years  without  otological
and  auditory  complaints  and  with  an  A  type  tympanometric
curve.30
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Exclusion  criteria  for  study  and  control  groups  were
s  follows:  individuals  with  illnesses  associated  with  ear
epercussion  (e.g., meningitis,  acoustic  trauma,  tinni-
us,  otorrhea,  history  of  recurrent  otitis  media  in  early
hildhood),  family  history  of  hearing  loss,  type  B  or  C  tym-
anometric  curve,30 and/or  refusal  to  sign  the  informed
onsent  (Appendix  I).  The  history  of  diseases  associated  with
ar  repercussion  was  veriﬁed  by  reviewing  medical  records.
nstruments  and  measures
he  protocol  followed  to  carry  out  the  tests  was  the  same
sed  in  the  otorhinolaryngology  and  speech  therapy  outpa-
ient  clinic  from  the  institution.  The  tests  were  performed
y  two  trained  speech  therapists.
Initially,  the  subject  was  submitted  to  an  ear  evalua-
ion  by  an  otorhinolaryngologist.  Then,  tests  of  acoustic
mpedance,  pure  tone  audiometry,  high  frequency  audiom-
try,  and  product-distortion  otoacoustic  emissions  were
onducted.  After  the  tests,  the  patient’s  medical  record  was
nalyzed  in  order  to  collect  data  relevant  to  the  study.
The  impedancemetry  examinations  were  performed
ith  the  AZ26  Impedancemeter  (Interacoustics  --  Denmark),
ith  tympanometry  and  a  survey  of  contralateral  acoustic
eﬂexes.  The  pure  tone  and  high  frequency  audiometry
ests  were  performed  with  the  Siemens  Unity  PC  audiome-
er  (Germany),  calibrated  in  dB  HL  according  to  ANSI
tandard  3.6-1989  with  the  use  of  HDA  2000  air  and  bone
onduction  B-71  phones.  Pure  tone  audiometry  by  air  and
one  conduction  was  performed  at  250--16,000  Hz  and
t  500--4000  Hz,  respectively.  All  audiological  tests  were
erformed  by  two  trained  speech  therapists  using  the  same
valuation  protocol.
The  criteria  of  normality  used  for  pure  tone  audiometry
ere  the  International  Bureau  for  Audiophonology  (Bureau
nternational  d’Audiophonologie  [BIAP])  classiﬁcation,  in
hich  the  average  of  the  frequencies  of  500,  1000,  2000,
nd  4000  Hz  <20  dB  HL  is  considered  as  normal  hearing.  For
igh  frequencies  (9000--16,000  Hz),  thresholds  up  to  25  dB
L  were  used  as  a  criterion  of  normality,  as  documented  in
revious  studies  of  normal  hearing  individuals.31--34
The  distortion-product  otoacoustic  emissions  test  was
onducted  in  an  acoustically  treated  room  with  the  ILO  292
ystem  (Otodynamics  --  England).  The  examination  was  per-
ormed  in  the  frequencies  of  1000,  1500,  2000,  3000,  4000,
nd  6000  Hz.  A  probe  was  inserted  into  the  patient’s  ear,
ith  an  audible  stimulus  simultaneously  generated  by  two
ure  tones  of  different  frequencies  (F1  and  F2),  in  which
1  =  65  dB,  F2  =  55  dB,  and  F2/F1  =  1.22.  The  test  was  ana-
yzed  by  a  DP-gram  chart,  and  presence  of  response  was
onsidered  as  the  ﬁnding  of  amplitudes  equal  to  or  greater
han  3  dB  SPL  above  the  noise  level.35
tatistical  analysisuantitative  variables  were  expressed  as  mean  and  standard
eviation  or  median  and  interquartile  range.  Categorical
ariables  were  described  by  absolute  and  relative  frequen-
ies.
5 Geyer  LB  et  al.
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Table  1  Sample  characterization.
Variable  Study  group
(n  =  39)
Control  group
(n =  36)
p-Value
Age  (years),
mean  ±  SD
13.0  ±  3.2  12.3  ±  4.1  0.420a
Age  group,  n  (%)  0.223b
<12  years  11  (28.2)  16  (44.4)
12--17 years  24  (61.5)  15  (41.7)
>18 years  4  (10.3)  5  (13.9)
Gender,  n  (%) 0.076b
Male  22  (56.4) 12  (33.3)
Female  17  (43.6) 24  (66.7)
Mutation,  n  (%)  --
Delta  F508  23  (92.0)  --
R553X 1  (4.0)  --
L543X  and  A561E  1  (4.0)  --
AG courses,  n  (%)  --
<10 33  (84.6)  --
>10 6  (15.4)  --
SD, standard deviation; AG, aminoglycosides.
a
i
6
e92  
To  compare  means  between  groups,  Student’s  t-test  for
ndependent  samples  was  applied.  In  the  case  of  asymmetry,
he  Mann--Whitney  test  was  used.
In  the  comparison  of  proportions,  Fisher’s  exact  test  was
sed.
The  signiﬁcance  level  was  set  at  5%  (p  ≤  0.05)  and  analy-
es  were  performed  using  SPSS  software,  version  18.0.
esults
he  sample  consisted  of  75  subjects:  SG  =  39  and  CG  =  36.
he  mean  age  was  13.0  (±3.2)  and  12.3  (±4.1)  years  for  the
G  and  CG,  respectively.  The  participants’  age  range  was
--20  years.  Twenty-two  subjects  in  the  SG  (56.4%)  and  12
n  the  CG  (33.3%)  were  male.  Table  1  shows  the  results  of
he  descriptive  analysis  of  age  and  gender  variables  for  each
roup,  genetic  mutations  in  CF,  and  number  of  intravenous
G  cycles  received  by  SG  participants.
There  was  no  statistically  signiﬁcant  difference  in  age
nd  gender  variables  between  the  SG  and  CG,  indicating  that
he  subjects  were  similar  in  these  aspects.  Therefore,  the
ample  was  analyzed  without  reference  to  these  variables.
n  the  analysis  of  auditory  thresholds  between  right  and  left
ar,  a  statistically  signiﬁcant  difference  was  noted  only  in
he  frequency  of  250  Hz  in  the  SG;  in  other  frequencies  and
n  the  CG  there  was  no  such  a  difference.  For  this  reason,
he  ears  were  analyzed  with  the  use  of  their  means  at  each
requency.
When  auditory  thresholds  were  compared  between
roups,  the  SG  had  signiﬁcantly  higher  thresholds  at
50  Hz,  1000  Hz,  8000  Hz,  9000  Hz,  10,000  Hz,  12,500  Hz,
nd  16,000  Hz.  The  mean  values  at  250--8000  Hz  and  at
000--16,000  Hz  were  signiﬁcantly  higher  in  the  SG  (Table  2).
The  SG  showed  a  higher  prevalence  of  hearing  loss  by  HFA
p  = 0.004)  (Fig.  1).  Using  PTA  in  the  range  of  250--8000  Hz,
either  group  exhibited  abnormalities.
d
S
(
Table  2  Comparison  of  hearing  thresholds  (dB  HL)  between  grou
Frequency  (Hz)  Study  group(n  =  39)  
Md  (P25--P75)  
250  5  (2.5--7.5)  
500 5  (2.5--10)  
1000 2.5  (0--5)  
2000 5  (2.5--7.5)  
3000 5  (2.5--7.5)  
4000 5  (2.5--7.5)  
6000 7.5  (5--12.5)  
8000 7.5  (5--15)  
Mean 250--8000  Hz  5.9  (3.4--8.1)  
9000 5  (2.5--15)  
10,000 5  (2.5--10)  
11,200 7.5  (2.5--15)  
12,500 5  (2.5--10)  
14,000 2.5  (0--12.5)  
16,000 2.5  (0--22.5)  
Mean 9000--16,000  Hz  4.6  (2.9--11.7)  
a Mann--Whitney test.a Student’s t-test.
b Chi-squared test (Pearson).
The  SG  showed  a  signiﬁcantly  higher  prevalence  of  DPOAE
lteration  when  compared  to  the  CG  (p  =  0.001),  as  shown
n  Fig.  2.
The  SG  presented  more  DPOAE  alterations  at  1000  Hz  and
000  Hz  in  both  ears  (Table  3),  when  comparing  right  and  left
ars  at  each  frequency  and  for  each  group.  No  signiﬁcant
ifference  between  the  ears  was  noted  (p  >  0.20).
When  comparing  DPOAE  amplitudes  between  groups,  the
G  had  lower  amplitudes  at  1000  Hz,  1400  Hz,  and  6000  Hz
Table  4).  When  comparing  left  and  right  ears  with  respect
ps.
Control  group(n  =  36)  p-valuea
Md  (P25--P75)
5  (0--5)  0.036
5  (2.5--7.5)  0.055
2.5  (0--2.5)  0.042
3.8  (0--5)  0.092
5  (2.5--5)  0.444
5  (2.5--6.9)  0.313
7.5  (5--10)  0.533
5  (2.5--7.5)  0.003
4.4  (2.3--5.9)  0.016
5  (2.5--7.5)  0.022
2.5  (0--5)  0.002
5  (2.5--7.5)  0.096
2.5  (0--5)  0.034
0  (0--2.5)  0.160
0  (0--0)  <0.001
2.9  (1.8--5.0)  0.005
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Figure  2  DPOAE  in  study  and  control  groups.  DPOAE,
d
s
HFigure  1  Alterations  in  HFA  in  study  and  control  groups.  HFA,
high frequency  audiometry.
to  DPOAE  amplitude,  there  was  signiﬁcant  difference  only
at  4000  Hz  in  the  SG  (p  =  0.037).
We  found  that  DPOAE  alterations  occurred  when  testing
high  frequencies,  both  in  the  study  group  with  normal  HFA
(66.7%)  and  in  the  group  with  HFA  alterations  (91.7%),  albeit
more  often  in  the  latter.  However,  the  statistical  analysis
h
i
Table  3  Comparison  of  alterations  in  DPOAE  by  frequency  and  by
Frequency  (Hz)  Ear  Study  group(n  =  3
1000 Right  10  (25.6)  
Left 8  (20.5)  
1400 Right 3  (7.7)  
Left 3  (7.7)  
2000 Right 5  (12.8)  
Left 2  (5.1)  
2800 Right 6  (15.4)  
Left 5  (12.8)  
4000 Right 6  (15.4)  
Left 9  (23.1)  
6000 Right 13  (33.3)  
Left 16  (41.0)  
a Fisher’s exact test.
Table  4  Comparison  of  amplitudes  (dB  SPL)  of  DPOAE  between  g
Frequency  (Hz)  Ear  Study  group(n  =  3
Md  (P25--P75)  
1000 Right  10.1  (5.5--15.3)  
Left 9.2  (5.5--15.2)  
1400 Right 16.0  (6.8--19.0)  
Left 14.5  (6.9--18.2)  
2000 Right 12.6  (6.5--16.9)  
Left 10.8  (6.4--16.0)  
2800 Right 11.2  (6.7--15.3)  
Left 10.2  (4.5--13.8)  
4000 Right 9.2  (2.0--14.8)  
Left 10.2  (1.4--13.8)  
6000 Right 5.6  (−3.2  to  12
Left 3.6  (−4.1  to  10
dB SPL, decibel sound pressure level.
a Mann--Whitney test.istortion-product  otoacoustic  emissions.
howed  that  there  was  no  association  between  changes  in
FA  and  in  DPOAE  for  SG  participants  (p  =  0.131)  (Fig.  3).
There  was  a  signiﬁcant  association  between  changes  in
earing  thresholds  by  HFA  with  number  of  AG  courses  admin-
stered  (p  =  0.005).  The  administration  of  more  than  ten
 ear  between  groups.
9)  Control  group(n  =  36)  p-Valuea
2  (5.6)  0.040
1  (2.8)  0.029
1  (2.8)  0.616
0  (0.0)  0.241
0  (0.0)  0.055
2  (5.6)  1.000
3  (8.3)  0.483
1  (2.8)  0.202
2  (5.6)  0.265
3  (8.3)  0.154
1  (2.8)  0.002
3  (8.3)  0.003
roups.
9)  Control  group(n  =  36)  p-Valuea
Md  (P25--P75)
11.2  (8.9--17.6)  0.168
13.3  (9.6--7.2)  0.028
15.6  (13.2--19.1)  0.528
16.2  (13.0--20.2)  0.041
14.2  (8.5--18.8)  0.233
14.1  (7.8--18.8)  0.051
12.4  (5.4--16.1)  0.451
11.0  (7.4--15.7)  0.148
14.4  (4.7--17.6)  0.166
11.2  (7.4--16.6)  0.072
.2)  8.7  (2.0--12.7)  0.102
.2)  9.7  (4.4--14.3)  0.007
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migure  4  Association  between  number  of  AG  cycles  and  HFA
lteration.  AG,  aminoglycosides;  HFA,  high  frequency  audiome-
ry.
ourses  of  intravenous  AG  was  associated  with  a  higher
revalence  of  HFA  alterations  (Fig.  4).
iscussion
FA  is  described  as  the  most  effective  method  for  early
etection  of  cochlear  alterations  due  to  ototoxicity.23,29,36
ts  use  is  still  limited,  due  to  lack  of  standardization  of
alibration  and  of  normality  parameters,16 particularly  in
he  pediatric  population,  because  of  low  test  reliability  in
hildren  under  7  years  of  age.37
Conversely,  evoked  otoacoustic  emissions  is  a  quick  and
bjective  test,  showing  a  great  advantage  for  both  pediatric
nd  adult  population,  who  often  fail  to  respond  appro-
riately  to  audiometry  tests,  due  to  the  disease  and  its
reatment.22,38 Considering  the  fact  that  otoacoustic  emis-
ions  may  exhibit  alterations  even  in  individuals  with  normal
hresholds  in  the  face  of  an  early  impairment  of  outer
air  cells,  this  procedure  is  widely  used  in  ototoxicity
onitoring.11,39
Considering  that  one  of  the  major  causes  of  ototoxicity
s  the  use  of  aminoglycosides,  and  that  CF  patients  receive
epeated  courses  of  this  type  of  drug,  this  population  is  at
igh  risk  of  developing  cochlear  alterations.7--10
By  analyzing  the  sample,  there  was  no  signiﬁcant  dif-
erence  in  male  versus  female  thresholds,  as  Abujamra
t  al.  also  found.29 Although  these  authors  have  studied  the
c
a
r
cGeyer  LB  et  al.
ffects  of  other  type  of  ototoxic  drug  (cisplatin),  they  also
eriﬁed  no  signiﬁcant  differences.
Neither  was  a  signiﬁcant  difference  detected  in  right
s.  left  ear  thresholds,  and  for  this  reason  the  ears’  mean
as  used  to  represent  such  thresholds.  In  studies  with  nor-
al  hearing  individuals,  Sahyeb  et  al.32 and  Sá  et  al.33 also
etected  no  difference  between  the  ears  using  PTA  and  HFA.
When  comparing  hearing  thresholds  obtained  by  PTA
250--8000  Hz)  and  HFA  (9000--16,000  Hz)  between  groups,
igniﬁcantly  higher  thresholds  were  observed  in  the  study
roup,  with  the  largest  differences  occurring  in  HFA.  Hear-
ng  loss  was  not  observed  in  PTA;  however,  HFA  detected  high
revalence  of  hearing  loss  in  the  study  group.  These  ﬁndings
emonstrate  the  importance  of  using  HFA  in  monitoring  CF
atients.19,40
These  results  differ  from  those  obtained  by  Martins
t  al.,41 who  observed  hearing  loss  at  conventional  frequen-
ies  and  at  high  frequencies  in  their  patients.  However,
l-Malky  et  al.42 found  hearing  loss  only  at  8000--20,000  Hz
y  HFA  and  reduced  amplitudes  using  DPOAE,  which  agrees
ith  the  present  ﬁndings.  In  that  study,  the  authors  highlight
he  fact  that  although  the  hearing  loss  is  associated  with  high
G  exposure,  it  only  occurred  in  21%  of  the  exposed  group.
aced  with  this  fact,  the  authors  suggest  that  there  may  be
ther  factors  responsible  for  hearing  loss.
In  the  present  study,  higher  number  of  alterations  by
requency  and  also  lower  amplitudes  in  DPOAE  were  noted
n  the  SG  vs.  CG,  even  with  normal  hearing  thresholds  up
o  8000  Hz.  This  ﬁnding  supports  the  study  of  Stavroulaki
t  al.,8 who  found  decreased  amplitudes  of  DPOAE  at  fre-
uencies  above  3000  Hz  in  children  with  CF  after  treatment
ith  gentamicin.  Mulheran  et  al.,24 Katbamna  et  al.,43 and
atbamna  et  al.44 obtained  similar  outcomes,  but  these
uthors  used  different  assessment  methods  of  DPOAE.
When  trying  to  establish  a  potential  association  between
lterations  in  DPOAE  and  alterations  in  HFA,  since  the  alter-
tions  in  DPOAE  occurred  more  frequently  in  individuals  with
lterations  in  HFA,  this  association  was  not  found.  This  result
ay  be  related  to  the  size  of  the  sample.  This  ﬁnding  dis-
greed  with  that  of  Arnold  et  al.,45 who  concluded  that
earing  at  high  frequencies  signiﬁcantly  inﬂuences  DPOAE
t  lower  frequencies.  However,  that  study  was  conducted
ith  healthy,  normal-hearing  young  adults.
With  respect  to  AG  effects,  it  is  known  that  repeated
ourses  of  treatment  and  its  duration  are  factors  related
o  increased  risk  of  ototoxicity.46,47 In  the  present  study  we
bserved  a signiﬁcant  association  between  receiving  more
han  ten  intravenous  AG  courses  and  HFA  alterations.  Some
uthors  found  similar  results,10,19,24 while  in  another  study
he  ﬁndings  were  different.40 In  their  study,  Mulheran  et  al.20
oncluded  that  there  is  possibly  an  increased  risk  of  ototox-
city  related  to  the  number  of  AG  courses  taken,  but  the
uthors  point  out  that  this  relationship  is  not  linear.  Due  to
he  low  prevalence  of  ototoxicity  found  in  CF  patients  vs.
ndividuals  without  the  disease  who  were  treated  with  AG,
ome  authors20,48 suggest  that  CF  itself  is  a  protective  factor
or  ototoxicity.  These  authors  suggest  that  such  protection
ay  be  due  to  altered  pharmacokinetics  and/or  underlies
hanges  in  CFTR,  but  that  more  research  is  needed  in  this
rea.  Furthermore,  it  is  known  that  CF  results  in  a  faster
enal  clearance  of  drugs,  including  AG,49,50 and  this  may  also
ontribute  to  reduced  ototoxicity.
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A  signiﬁcantly  higher  prevalence  of  DPOAE  alterations
in  SG,  with  the  presence  of  more  alterations  at  1000  and
6000  Hz  in  both  ears  and  with  lower  amplitudes  at  1000,
1400,  and  6000  Hz,  suggest  that  this  test  should  also  be  con-
ducted  in  CF  patients,  even  in  those  with  normal  hearing.
The  signiﬁcantly  elevated  hearing  thresholds  at  250;  1000,
8000,  9000,  10,000,  12,500,  and  16,000  Hz  and  the  exclusive
presence  of  HFA  alterations  in  30.8%  of  the  SG  suggest  that
this  assessment  should  be  incorporated  into  the  auditory
monitoring  of  CF  patients.
Conclusion
This  study  showed  that  a  signiﬁcant  number  of  CF  patients
who  received  repeated  AG  courses  demonstrated  HFA
and  DPOAE  alterations,  and  that  there  was  a  signiﬁcant
association  between  administration  of  more  than  ten
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h  frequency  hearing  thresholds  and  product-distortion
udy  hearing  tests  that  can  show  if  hearing  loss  occurs  in
eived.
study  group,  that  is,  the  group  of  participants  who  have  cystic
ancemetry,  and  otoacoustic  emissions.  The  total  duration  of
t  will  be  carried  out  is  that  a  wider  range  of  sounds  will  be
king  it  a  more  comprehensive  examination.  The  main  beneﬁt
re  the  frequencies  used  in  the  communication,  i.e.,  the
is  placed  inside  a  soundproof  booth  with  headphones  in  their
n  they  are  hearing  the  sound.  The  examination  has  an  average
nt’s  ears,  and  in  the  other  ear  a  probe  is  placed,  causing  slight
 is  ﬁve  minutes.
he  probe  sends  some  sounds.  The  average  duration  of  this  test
t  if  there  are  any  unpleasant  sensations,  any  of  them  may  be
bout  the  study  before  it  is  performed  and  during  its
se  to  participate  or  withdraw  their  consent  at  any  stage  of  the
care.
ensitive  data.  If  the  study  is  published,  the  participant’s  name
rticipation.
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